Biovica: A partly understandable overreaction earlier today - Redeye

The local and regional peer company, Arocell, withdrew the FDA application and may reapply a De Novo submission in due course. This has triggered a sharp negative reaction of 7-8% in Biovica. This is, in our view, a partly understandable negative overreaction. Our value proposition for Biovica remains a base case value of SEK 95 (Bull SEK 325 and Bear SEK 20).

Länk till analysen i sin helhet: https://www.redeye.se/research/818352/biovica-a-partly-understandable-overreaction-earlier-today?utm_source=finwire&utm_medium=RSS